NLS Pharmaceutics Submits Abstracts to ASCP Meeting
Ticker: NCEL · Form: 6-K · Filed: Jan 30, 2025 · CIK: 1783036
| Field | Detail |
|---|---|
| Company | Nls Pharmaceutics LTD. (NCEL) |
| Form Type | 6-K |
| Filed Date | Jan 30, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: research, conference
TL;DR
NLS Pharmaceutics is presenting research at the 2025 ASCP Annual Meeting.
AI Summary
On January 30, 2025, NLS Pharmaceutics Ltd. announced the submission of three research abstracts to the 2025 ASCP Annual Meeting. This filing incorporates the press release as Exhibit 99.1 and references its inclusion in various Form F-3 registration statements.
Why It Matters
The submission of research abstracts indicates progress in the company's scientific endeavors and potential for future presentations and publications.
Risk Assessment
Risk Level: low — This filing is a routine report of a press release and does not contain significant new financial or operational information.
Key Players & Entities
- NLS Pharmaceutics Ltd. (company) — Registrant
- 2025 ASCP Annual Meeting (event) — Submission destination for research abstracts
- January 30, 2025 (date) — Date of press release
FAQ
What is the main purpose of this Form 6-K filing?
The main purpose is to report a press release issued by NLS Pharmaceutics Ltd. on January 30, 2025, announcing the submission of three research abstracts to the 2025 ASCP Annual Meeting.
What is the title of the press release being filed?
The press release is titled "NLS Pharmaceutics Announces the Submission of Three Research Abstracts to the 2025 ASCP Annual Meeting."
What is the filing date of this report?
This report was filed on January 30, 2025.
What is NLS Pharmaceutics Ltd.'s principal executive office address?
The principal executive offices are located at The Circle 6, 8058 Zurich, Switzerland.
Into which of the Registrant's registration statements is this Form 6-K incorporated by reference?
This Form 6-K is incorporated by reference into the Registrant's Registration Statements on Form F-3, specifically File Nos. 333-282788, 333-262489, 333-268690, and 333-269220.
Filing Stats: 272 words · 1 min read · ~1 pages · Grade level 10.9 · Accepted 2025-01-30 08:00:09
Filing Documents
- ea0229151-6k_nlsphar.htm (6-K) — 11KB
- ea022915101ex99-1_nlsphar.htm (EX-99.1) — 11KB
- 0001213900-25-008084.txt ( ) — 24KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NLS Pharmaceutics Ltd. Date: January 30, 2025 By: /s/ Alexander Zwyer Name: Alexander Zwyer Title: Chief Executive Officer 2